With healthcare demand across ASEAN countries continuing to grow, medical infrastructure being upgraded and international demand for quality pharmaceuticals rising, Southeast Asia has become a key market for the global biopharmaceutical industry. To deepen regional cooperation and expand international business opportunities, Taiwan Green Cross General Manager Tsai-Ling Lin travelled to Bangkok, Thailand in early July 2026, taking part in a series of major international pharmaceutical exhibitions and government-led trade promotion activities.
Taiwan Healthcare Delegation and the WHX / CPHI Exhibitions
The itinerary covered three key events in the Southeast Asian healthcare industry:
- Taiwan Medical Services and Healthcare Delegation: On 9 July, the General Manager attended the "Taiwan Medical Services and Healthcare Delegation to Thailand" at the InterContinental Bangkok, jointly organised by the Taiwan External Trade Development Council (TAITRA) and the Taiwan Food and Drug Administration (TFDA), holding in-depth business matchmaking sessions with local Thai healthcare institutions, distribution partners and government representatives.
- WHX Bangkok 2026 pavilion: In the Taiwan Pavilion organised by TAITRA at WHX Bangkok 2026 (World Health Expo), Taiwan Green Cross showcased Urokinase, its long-established core thrombolytic product, attracting enquiries from distributors and healthcare professionals across several countries.
- CPHI South East Asia 2026: From 8 to 10 July, the team also attended CPHI at the Queen Sirikit National Convention Center (QSNCC), holding discussions with biopharmaceutical representatives from Asia and Europe on new drug development, API supply chain strategy and regional distribution partnerships.
Remarks from General Manager Tsai-Ling Lin
The Southeast Asian market is full of momentum and potential, and Taiwan Green Cross has long been committed to quality and clinical value. Through TAITRA and TFDA's cross-border trade platforms, we aim on the one hand to continue building our presence in Southeast Asia and raise the international market share and brand recognition of Taiwan's own Urokinase; on the other, we are actively connecting with leading international pharmaceuticals and technologies, strengthening both the resilience and the diversity of Taiwan's pharmaceutical supply chain and bringing more clinically valuable treatment options to practice.
Expanding our international footprint
With many years of experience in pharmaceutical development and manufacturing, Taiwan Green Cross will continue to support government initiatives and take an active part in international exhibitions and overseas business matchmaking. Guided by the strategy of "rooted in Taiwan, connected to ASEAN, reaching the world", the company will deepen its relationships with Southeast Asian healthcare institutions and distribution partners to jointly raise the standard of regional healthcare.
About Taiwan Green Cross
Taiwan Green Cross focuses on prescription pharmaceuticals, medical devices and healthcare. We are committed to introducing and developing innovative medical technologies and products, offering clinical professionals and patients more complete treatment and care options, while actively expanding into international markets to advance the globalisation of Taiwan's healthcare industry.